Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 15/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.38 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5032306 | 0.92 | NR3C1 (0.39) | PGRNR3C1NR3C2AR | |
| SCHEMBL2392004 | 0.90 | NR3C1 (0.40) | PGRNR3C1NR3C2AR | |
| SCHEMBL2395886 | 0.86 | NR3C1 (0.41) | PGRNR3C1NR3C2AR | |
| SCHEMBL449776 | 0.86 | NR3C1 (0.45) | PGRNR3C1NR3C2AR | |
| SCHEMBL450303 | 0.85 | NR3C1 (0.43) | PGRNR3C1NR3C2AR | |
| SCHEMBL5032313 | 0.83 | PGR (0.41) | PGRNR3C1NR3C2ARSMN1; SMN2 | |
| SCHEMBL5034429 | 0.81 | PGR (0.53) | PGRNR3C1NR3C2AR | |
| SCHEMBL2395976 | 0.79 | PGR (0.41) | PGRNR3C1ARSMN1; SMN2 | |
| SCHEMBL14139133 | 0.79 | PGR (0.42) | PGRNR3C1NR3C2AR | |
| SCHEMBL5034716 | 0.78 | PGR (0.41) | PGRNR3C1ARSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1944290-A1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, NR5A1 | PGR 201/4885NR3C1 1/4885NR3C2 2/4885 |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | NR3C1, NR3C2, NR5A1 | PGR 257/4885NR3C1 1/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.